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The serotonin transporter (SERT) 
regulates extracellular levels of serotonin 
(5-hydroxytryptamine, 5HT) in the brain 
by transporting 5HT into neurons and glial 
cells. The human SERT (hSERT) is the 
primary target for drugs used in the 
treatment of emotional disorders, including 
depression. hSERT belongs to the solute 
carrier 6 (SLC6) family that includes a 
bacterial leucine transporter, LeuT, for 
which a high-resolution crystal structure 
recently has become available. LeuT has 
proved to be an excellent model for human 
transporters and has advanced the 
understanding of SLC6 transporter 
structure-function relationships. However, 
the precise structural mechanism by which 
antidepressants inhibit hSERT and the 
location of their binding pockets is still 
elusive. We have identified a residue 
(Ser438) located within the 5HT-binding 
pocket in hSERT to be a critical 
determinant for the potency of several 
antidepressants including the selective-
serotonin reuptake inhibitor citalopram 
and the tricyclic antidepressants 
imipramine, clomipramine and 
amitriptyline. A conservative mutation of 
Ser438 to a threonine (S438T) selectively 
increased the Ki for these antidepressants 
up to 175-fold. The effect of introducing a 
protein methyl group into the 5HT-binding 
pocket by S438T were absent or reduced 
for analogues of these antidepressants 
lacking a single methyl group. These 
results suggest that these antidepressants 
interact directly with the side chain of 
Ser438 during binding to hSERT; implying 
an overlapping localization of substrate 
and inhibitor-binding sites in hSERT 
suggesting that antidepressants function by 
a mechanism that involves direct occlusion 
of the 5HT binding site. 
Drugs that inhibit SERT such as the 
tricyclic antidepressants (TCAs) and the 
selective serotonin reuptake inhibitors 
(SSRIs) are widely used to treat emotional 
disorders such as depression and anxiety (1). 
Despite the vast clinical significance of SERT 
as a drug target, structural aspects of drug 
recognition and inhibition are poorly 
understood. SERT belongs to the solute 
carrier 6 (SLC6) family that includes 
transporters for neurotransmitters such as γ-
aminobutyric acid, norepinephrine, dopamine, 
and glycine. Until recently, the structural 
mechanism underlying SLC6 transporter 
function was largely unknown. However, a 
recent high-resolution crystal structure of a 
bacterial homolog to mammalian SLC6 
transporters, LeuT (2), has provided the first 
structural insight into SLC6 transporter 
function and has proven an excellent platform 
for constructing experimentally validated 
three-dimensional models of binding pockets 
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for ions, substrates and inhibitors in the 
human transporters (3-8). 
Similar progress in understanding the 
structural mechanism of antidepressant 
inhibition of SERT has so far been absent. 
Prior to arrival of the LeuT structure, 
mutagenesis studies have identified several 
residues at which mutations can perturb 
potency or binding affinity of SSRIs and 
TCAs (Fig. 1). LeuT-based homology models 
of SERT show that several of these residues 
are localized within the 5HT-binding pocket; 
thus supporting a model in which 
antidepressants bind within or in close 
proximity to the substrate-binding pocket (9). 
A competitive mechanism is supported by 
pharmacological studies that show the 
potency of TCAs and SSRIs at hSERT is 
sensitive to 5HT concentration (10-12). 
However, conclusive interpretation of 
mutagenesis studies have been hampered by 
the lack of structural information on hSERT 
and a consensus regarding the location of the 
binding sites for TCAs and SSRIs have 
therefore not been reached. Recently, this lack 
of consensus was further substantiated when 
two studies found LeuT to be inhibited by 
TCAs in a binding pocket outside the 
substrate-binding site (Fig. 2A) (13,14). 
Based on mutations of ortholog residues in 
the human monoamine transporters, Zhou et 
al. (13) proposed that the primary effects of 
TCAs and possibly SSRIs are mediated by 
binding in this region in hSERT. Here, we 
report that a subtle mutation in hSERT, 
S438T, dramatically affects the potency of 
antidepressants containing a dimethyl 
aminopropyl chain. This effect is reduced or 
absent in analogues of these antidepressants 
in which a single methyl is removed from the 
dimethylamino moiety; implicating that 
antidepressants and Ser438 are in close proximity. 
Comparative modelling of hSERT suggests 
Ser438 to be located within the 5HT-binding 
pocket. In contrast, mutations within the 
region in hSERT orthologous to the TCA-
binding site found in LeuT did not decrease 
antidepressant potency significantly. 
Combined with previous data, our results 
could clarify the current disagreement 
regarding the position of the binding pocket 
for antidepressants in hSERT. 
 
Experimental procedures 
 
Chemicals- Dulbecco's modified Eagle's 
medium (DMEM), foetal bovine serum, 
trypsin and penicillin–streptomycin were 
purchased from Invitrogen (Carlsbad, CA, 
USA). Cell culture flasks and 96-well plates 
were from NUNC (VWR International, West 
Chester, PA, USA). [3H]5HT (20.3 Ci/mmol) 
and MicroScint-20 scintillation cocktail were 
obtained from PerkinElmer (Waltham, MA, 
USA). [3H]MADAM (71.0 Ci/mmol) was 
from GE Healthcare (Buckinghamshire, UK). 
Imipramine, desipramine, clomipramine, 
monomethyl-clomipramine, amitriptyline, 
nortriptyline, citalopram, monomethyl-
citalopram, des-methyl-citalopram, (S)-
citalopram, (S)-monomethyl-citalopram, 
venlafaxine, sertraline, duloxetine, fluoxetine, 
paroxetine, nisoxetine, MADAM and 
aminoethyl-citalopram were kindly provided 
from H. Lundbeck A/S, Copenhagen, 
Denmark. RTI-55 was purchased from ABX 
(Radeberg, Germany). 
Molecular biology- The mammalian 
expression plasmid pcDNA3-hSERT 
containing human SERT cDNA has been 
described previously (15). Generation of 
point-mutations (I179D, I179F, D400F, 
D400K, D400L, L406D, L406F, L406K, 
S438T, V489D, V489F, V489K, K490D, 
K490F and K490T) in pcDNA3-hSERT was 
performed by site-directed mutagenesis using 
the QuickChange mutagenesis kit (Stratagene, 
Carlsbad, CA, USA), followed by sequencing 
of the entire gene (MWG Biotech, 
Martinsried, Germany). 
Cell culturing and expression of human 
SERTs- COS7 cells (ATCC, Manassas, VA, 
USA) were cultured in DMEM media with 
10% fetal bovine serum, 100 U/mL penicillin 
and 100 µg/mL streptomycin at 37 °C in a 
humidified 5% CO2 environment. Cells were 
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transfected using TransIT DNA transfection 
reagent following the protocol supplied by the 
manufacturer. Prior to transfection confluent 
cells growing in monolayer were resuspended 
in DMEM at a concentration of 1.3 x 106 
cells/mL. Per 96-well plate, 6 µg DNA and 18 
µL transfection reagent were mixed in 0.6 mL 
DMEM and incubated at 20 °C for 20 min. 
Subsequently this mixture was added to the 
cell suspension and immediately afterwards 
the cells were dispensed into white 96-well 
plates at 50% confluence. 
Uptake assays- Uptake assays were 
performed +40 h after transfection. Cells were 
washed twice with PBSCM buffer (in mM: 
NaCl, 137; KCl, 2.7; Na2HPO4, 4.3; KH2PO4, 
1.4; CaCl2, 0.5; MgCl2, 0.5) prior to uptake 
experiments. In inhibition studies cells were 
incubated with increasing concentration of 
inhibitors in PBSCM and 50 nM or 150 nM 
[3H]5HT at 20 °C for 30 min. In saturation 
experiments, cells were incubated at 20 °C for 
10 min in PBSCM containing increasing 
concentrations of [3H]5HT diluted 10-fold 
with unlabeled 5HT. Uptake was terminated 
by washing three times with PBSCM. The 
amount of accumulated [3H]5HT was 
determined by solubilising cells in scintillant 
with counting of plates in a Packard 
TopCounter (Packard Inc., Prospect, CT, 
USA). Non-specific uptake was determined as 
uptake in non-transfected cells. Assays were 
carried out in triplicate and repeated at least 6 
times.  
Cell membrane preparation and radioligand-
binding displacement assay- COS7 cells 
transiently expressing WT or S438T hSERT 
growing in 150 mm tissue culture petri plates 
were washed with PBS with 1 mM EDTA to 
detach from the plate. Cell suspension was 
centrifuged at low speed (700 x g) at RT for 5 
min. Cell pellet was resuspended in cold H2O 
and frozen at -20°C for 1 h. The suspension 
was thawed on ice and subjected to 10-15 
passages through a 21 gauge needle to disrupt 
cells. Homogenate was transferred to cold 2-
ml microcentrifuge tubes and centrifuged at 
18,000 x g at 4 °C for 30 min. Supernatant 
was aspirated, and the pellet was resuspended 
in PBSCM. Protein concentration of the 
resulting membrane preparation was 
determined according to the BCA method 
using the Pierce BCA Protein Assay 
(ThermoFischer, Rockford, IL). Membranes 
were used directly for binding experiments or 
stored at -80 °C until use. For saturation 
binding studies, increasing concentrations of 
[3H]MADAM and 30-50 µg total membrane 
protein per sample were combined in 96-well 
plates and total volume adjusted to 200 µL 
per sample. Binding was allowed to preceed 
for 2 h at room temperature with gentle 
rocking. Subsequently, membranes were 
transferred to 96-well glass fibre filter plates 
(Unifilter C, PerkinElmer) preincubated with 
0.1% polyethyleneimine using a Packard Bell 
cell harvester and washed four times with 
water. Non-specific binding was determined 
in parallel at membranes from non-transfected 
COS7 cells. Filter plates were dried and   
soaked in scintillant followed by counting in a 
Packard Topcounter (Packard Inc., Prospect, 
CT, USA). Saturation binding assays were 
carried out in dublicate and repeated at least 
five times.  
For competition binding assays, 30-50 µg 
total membrane protein was incubated with a 
fixed concentration of [3H]MADAM (5 nM 
for WT and 25 nM for S438T) in the presence 
of increasing concentrations of inhibitor using 
the same protocol as for saturation binding 
experiments. Competition binding assays 
were carried out in dublicate and repeated at 
least three times.  
Molecular modelling- The crystal structure of 
LeuT (PDB accession code 2A65) was used 
to construct a model of hSERT using the 
MODELLER comparative modelling package 
(16)  following the alignment of SERT and 
LeuT by Beuming et al. (17). The sodium 
ions were inserted manually in the same 
position as in 2A65. 5HT was docked into the 
hSERT model using the Glide docking 
program (18,19) in Maestro (Schrödinger, 
LLC, version 8.5) with default settings 
applied. Since LeuT was crystallized with the 
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small substrate, leucine, the cavity is rather 
small for accommodating larger ligands. 
Therefore, we used a flexible docking 
approach using the induced fit docking (IFD) 
procedure in Maestro for docking of (S)-
citalopram and imipramine. Since the side 
chain of Phe335 is placed on the extracellular 
side of the binding site as an aromatic lid, this 
side chain prevents access into the cavity. 
Therefore, the option in the IFD workflow, in 
which this residue initially is mutated to an 
Ala residue and then added again later in the 
refinement, was used.  
Data analysis- All data analysis was 
performed using Prism 4.0 software 
(GraphPad Inc, San Diego, CA, USA). For 
determination of IC50 values dose-response 
data from [3H]5HT uptake inhibition assays 
were fitted by the equation:  
 
% specific uptake = 100/(1 + 10^{(logIC50-
log[inhibitor]) x Hill slope}) 
  
, where IC50 is the concentration of inhibitor 
that produces a half-maximal inhibition of 
uptake. For determination of Km (the 
Michaelis-Menten constant) and Vmax 
(maximal uptake rate) the uptake rate was 
plotted as function of substrate concentration 
and fitted by the equation: 
 
Uptake rate = (Vmax x [5HT])/(Km + [5HT]) 
 
IC50 values were converted to Ki  values using 
the Cheng-Prusoff equation (20):  
 
Ki = IC50/(1+([L]/Km)) 
 
, where [L] is the concentration of [3H]5-HT. 
Ki values were compared using Student's t-test 
unless otherwise indicated. 
For determination of Kd (the dissociation 
constant) data from saturation binding 
experiments were fitted to the equation: 
 
Specific binding = (Bmax x [ligand])/(Kd + 
[ligand]) 
 
, where Bmax is the maximal binding, and Kd is 
the concentration of ligand required to reach 
half-maximal binding. For determination of 
IC50, dose response data from competition 
binding experiments were fitted to the 
equation: 
 
Specific binding = 100/(1 + 
10^{log[inhibitor]-logIC50}) 
 
, where IC50 is the concentration of inhibitor 
that produces a half-maximal binding of 
radioligand. IC50 values were converted to Ki  
values using the Cheng-Prusoff equation: 
 
Ki = IC50/(1+([L]/Kd)) 
  
, where [L] is the concentration of 
[3H]MADAM.  
 
RESULTS 
 
The conservative mutation S438T 
selectively affects hSERT inhibitors. The 
importance of Ser438 for antidepressant 
binding was initially discovered during a 
LeuT-guided mutational study of hSERT 
aiming at identifying residues forming the 
binding-pocket for the SSRI citalopram 
(Andersen et al., Soc. Neurosci. Abstr. 248.15, 
2007). Our initial observation was that a 
conservative mutation of Ser438 to a 
threonine (S438T), thus introducing only a 
methyl group, increased the Ki for citalopram 
inhibition of [3H]5HT uptake 175-fold (Fig. 
2C-D) (P<0.0001; N=6, paired t test). The Km 
value for 5HT transport was 6.9-fold 
decreased by this mutation (0.97 ± 0.09 µM, 
N=9, for WT vs. 0.14 ± 0.02 µM, N=4, for 
S438T, P<0.0001, t test), and Vmax was 5.5-
fold decreased (6.6 ± 1.1 pmol/well/minute, 
N=9, for WT vs. 1.2 ± 0.1 pmol/well/minute, 
N=4, for S438T; P<0.0001, t test). 
Concomitant characterization of 11 
prototypical hSERT inhibitors showed a 
remarkably selective influence of S438T on 
inhibitor potency (Fig. 2C; Table 1; 
supplementary Fig. S1; supplementary Table 
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S1). Specifically, seven inhibitors showed 
decreased Ki at S438T compared to WT 
ranging from 7-fold for the TCA imipramine 
to 450-fold for the cocaine analog RTI-55. 
The remaining compounds displayed no or 
less than a 2-fold change in Ki. 
Ser438 is located in the 5HT-binding 
pocket. Structural sequence alignment show 
that Ser438 in hSERT corresponds to Ser355 
in LeuT (Fig. 2B)(2,17,21). In LeuT, Ser355 
is located in the substrate-binding pocket 
interacting directly with the alkyl side chain 
of the substrate leucine and a Na+ ion. 
Previous experiments with hSERT have 
identified several residues important for 
substrate recognition. Most of these residues 
align well with residues in LeuT that form the 
substrate-binding pocket (21); substantiating 
that LeuT is a valid structural model of the 
5HT-binding pocket in hSERT. In particular, 
evidence for a key role of Ser438 in 5HT 
recognition has recently been shown in 
hSERT (8). In LeuT, Ser355 is located 5 Å 
from Gly24, which is replaced by an aspartate 
in hSERT (Fig. 2B; Asp98 in hSERT) (2). 
This aspartate residue is conserved in all 
SLC6 transporters that transport monoamines 
(5HT, dopamine, norepinephrine), and several 
lines of experimental data have established 
that the aspartate carboxylate group 
coordinates the primary amino group of 
monoamines (7,8,22-24). All TCAs and 
SSRIs contain an essential amino group that 
has been proposed to form similar interactions 
with Asp98 in hSERT (23). In our LeuT-
based homology model of hSERT shows that 
Ser438 is located within 4 Å of Asp98 (Fig. 
2B). Considering this close proximity of 
Asp98 to Ser438 in hSERT, the S438T 
mutation might thus specifically perturb the 
ability of the substrate-binding pocket to 
accommodate the aminopropyl chain of 
citalopram. 
Reciprocal modification of SSRIs and 
TCAs revoke the effect of the S438T mutation. 
We hypothesized that a citalopram analogue 
with a shorter aminoalkyl chain would be less 
affected by the S438T mutation. We tested 
this idea by evaluating the effect of S438T on 
a citalopram analog containing a shorter 
aminoalkyl chain and we found no difference 
in Ki between WT and S438T hSERT (Fig. 
2D; supplementary Table S1) (P=0.11, N=6; 
t-test). This striking effect indicates that 
S438T may introduce a steric clash between 
the dimethyl aminopropyl chain of citalopram 
and the γ-methyl group of the threonine (Fig. 
3). To further explore this, we determined the 
effect of S438T on citalopram analogs where 
one or two methyl groups were removed from 
the aminopropyl chain; anticipating these 
subtle modifications to gradually decrease the 
effect of the S438T mutation on inhibitor 
potency. Indeed, Ki for the monomethyl and 
des-methyl citalopram analogs (Fig. 4; Table 
1) were remarkably less affected by the 
S438T mutation displaying only a 5.8-fold 
and 1.7-fold loss in potency, respectively, 
compared to the 175-fold decrease observed 
for citalopram (P<0.0001, N=6 [citalopram vs. 
monomethyl-citalopram]; P<0.0001, N=6 
[monomethyl-citalopram vs. des-methyl-
citalopram]; t test). This demonstrates that the 
addition of the protein methyl group at 
position 438 is compensated by removal of 
methyl groups on the aminopropyl chain of 
the ligand. We also characterized (S)-
citalopram, which is the more potent 
enantiomer of the racemic citalopram, and its 
monomethyl analogue, (S)-monomethyl-
citalopram at WT and S438T and observed a 
similar pattern with 320-fold loss of potency 
for (S)-citalopram compared to only a 12-fold 
loss of potency for (S)-monomethyl-
citalopram (P=0.0003, N=6-8 [(S)-citalopram 
vs. (S)-monomethyl-citalopram]; t test) (Table 
1). 
The ability of the S438T mutation to 
differentiate between one or two methyl 
groups on the aminopropyl chain of 
citalopram indicates that Ser438 is a direct 
contact site for citalopram. In order to 
investigate the generality of this phenomenon, 
we investigated the effect of S438T on 
another major class of antidepressants, the 
TCAs. The TCA imipramine contains the 
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same dimethyl aminopropyl chain as 
citalopram, and desipramine is the 
monomethyl analogue of imipramine. This 
close analogy to citalopram and monomethyl-
citalopram allowed us to test if the potency at 
hSERT of these TCAs also is differentially 
affected by the S438T mutation following 
similar patterns. We therefore determined the 
Ki for imipramine and desipramine at WT and 
S438T (Fig. 4; Table 1). Indeed, we observed 
a similar pattern where the S438T mutation 
induced a 7.1-fold loss of potency for the 
dimethyl analogue imipramine in contrast to a 
much smaller 1.7-fold loss for the 
monomethyl analogue desipramine (P<0.0001, 
N=6 [imipramine vs. desipramine]; t test).  
Next, we characterized clomipramine 
and its monomethyl analog, monomethyl-
clomipramine, at WT and S438T and 
observed the same pattern (Fig. 4; Table 1); 
clomipramine having an 11.4-fold loss of 
potency whereas monomethyl-clomipramine 
displayed only a 4.0-fold loss (P=0.0084, 
N=8 [clomipramine vs. monomethyl-
clomipramine]; t test). Finally, we 
characterized the TCAs amitriptyline and 
nortriptyline, differing in the same way as the 
other TCAs (Fig. 4; Table 1). Amitriptyline 
showed an 11.5-fold loss of potency whereas 
nortriptyline had no change of potency on 
S438T compared to WT (P<0.0001, N=8 
[amitriptyline vs. nortriptyline]; t test).  
Competitive binding analysis of the 
S438T mutation. Rather than directly 
perturbing ligand interaction with hSERT, the 
effects of the S438T mutation on the 
inhibitory potency of antidepressants could be 
caused via long range allosteric modification 
of the inhibitor-binding pocket. Therefore, we 
performed [3H]MADAM competitive binding 
assays to test if S438T-induced changes in 
inhibitory potency reflect a concomitant loss 
in binding affinity of the inhibitors (Table 2). 
[3H]MADAM was used to label SERT since 
the apparent Ki-value of this radioligand was 
almost insensitive to the S438T mutation in 
contrast to other hSERT radioligands 
([3H]imipramine, [3H]paroxetine, 
[3H]escitalopram, [125I]RTI-55). Saturation 
binding analysis of [3H]MADAM showed that 
the Kd-value was increased at hSERT S438T 
compared to hSERT WT (1.3 ± 0.3 nM, N=6, 
for WT vs. 21.6 ± 3.7 nM, N=5, for S438T). 
Results from the competition binding assays 
showed that the effects of the S438T mutation 
on inhibitor binding follow the same trends as 
observed in the functional uptake inhibition 
studies (Table 2), i.e. the affinity decrease 
caused by introduction of the protein methyl 
group in the S438T mutant was significantly 
smaller for all inhibitors containing a 
monomethyl aminopropyl chain than the 
affinity decrease observed for their dimethyl 
congeners. Notably, when we compare data 
from competition binding assays to the data 
obtained from the functional 5HT uptake 
inhibition assays, we observed that the loss of 
binding affinity was greatly amplified for 
inhibitors having a dimethyl propylamino 
chain compared to the loss in potency. For 
instance, citalopram showed a 175-fold loss 
of potency at the S438T mutant while the 
binding affinity was decreased by 2148-fold. 
The same dramatic effect of S438T on 
binding affinity compared to potency was 
observed for the dimethyl analogues 
imipramine (283- vs. 7-fold) and 
clomipramine (107- vs. 11-fold). In contrast, 
the impact of S438T on binding affinity of the 
monomethyl analogues was found to be in the 
same range as that observed in the functional 
assay (3- to 11-fold vs. 1- to 6-fold). Thus, 
data from the competition binding assays 
show that the S438T mutation indeed has a 
even more pronounced effect on the ability of 
hSERT to bind inhibitors with a dimethyl 
propylamine chain compared to their 
monomethyl congeners.     
Induced fit docking of citalopram and 
imipramine. The inhibitory potency of hSERT 
inhibitors containing a dimethyl aminopropyl 
moiety are more sensitive to the S438T 
mutation compared to their monomethyl 
congeners. However, citalopram is 
remarkable more affected by the mutation 
compared to the three TCA molecules having 
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a dimethyl aminopropyl chain (imipramine, 
clomipramine and amitriptyline). To better 
understand these differences, we performed 
induced fit docking of (S)-citalopram and the 
prototypical TCA, imipramine, into our 
homology model of hSERT (Fig. 5; 
supplementary Fig. S2). The dimethyl amino 
group of both inhibitors are stabilized by the 
carboxylate group of Asp98. However, the 
dimethyl amino group of (S)-citalopram is 
located in closer proximity of Ser438 
compared to the same moiety of imipramine 
(4Å vs. 6Å). Since the hydroxy group on the 
side chain of Ser438 also coordinates one of 
the sodium ions, it cannot interact with the 
antidepressants through a hydrogen-bond, but 
is important in defining the cavity around the 
amino group. Given the difference in 
proximity of the inhibitors and Ser438, we 
suggest that citalopram would be more 
sensitive to the introduction of a methyl group 
at Ser438 compared to imipramine. Since 
imipramine is located further away from 
Ser438 compared to (S)-citalopram, the steric 
clash between a methyl group on the dimethyl 
aminopropyl chain and the introduced protein 
methyl group at S438T would affect 
imipramine to a lesser extent than (S)-
citalopram. This idea is supported by the 
experimental results showing TCAs to be less 
affected by the S438T mutation compared to 
citalopram.  
Role of hSERT vestibule residues for 
antidepressant binding. The ability of S438T 
to discern the presence of methyl groups on 
antidepressants suggest that this residue is a 
direct contact point for these ligands; 
implicating the 5HT-binding pocket as a 
likely binding site for these inhibitors. In 
contrast, the TCA-binding pocket recently 
found in LeuT is located in a region that 
forms a vestibule in the substrate permeation 
pathway that is probably shared by all SLC6 
transporters (13,14,25,26). The orthologous 
region in hSERT could presumably form a 
secondary binding pocket for antidepressants 
and contribute to the inhibitory mechanism; 
by influencing the en route passage to the 
primary binding pocket or by allosteric 
modulating binding at the primary pocket. We 
therefore examined the contribution of this 
region in hSERT to antidepressant function 
by introducing a range of non-conservative 
mutations (Fig. 6; supplementary Table S2). 
Specifically, we introduced considerably 
different side chains at five positions in order 
to perturb potential molecular contact to the 
antidepressants. Of the resulting 14 mutants, 9 
had intact 5HT transport function, but none of 
these mutations increased Ki values 
significantly for (S)-citalopram, imipramine, 
or clomipramine. In contrast, a few mutants 
displayed slightly decreased Ki. Based on this 
lack of effect of vestibule mutations to perturb 
antidepressant potency, we suggest that this 
region in hSERT has minor influence on the 
inhibitory mechanism of TCAs and SSRIs. 
 
DISCUSSION 
 
Fundamental requirements for understanding 
the structural mechanism underlying 
antidepressant inhibition of hSERT include 
unambiguous identification of the location of 
inhibitor-binding site and elucidation of 
specific protein-ligand contacts. The LeuT 
structure has great potential to guide 
functional studies aiming at providing this 
information, but in order to take full 
advantage of this structural template, it is 
critically important to establish similarities 
and discrepancies between the bacterial 
transporter and its mammalian relatives. Zhou 
et al. (13) suggests TCAs and possibly SSRIs 
inhibit human monoamine transporters by the 
same mechanism as observed in LeuT; 
implicating that the primary binding site is 
located in the transporter vestibule, separated 
from the substrate-binding pocket. This 
hypothesis seems in conflict with the fact that 
SSRIs and TCAs act as competitive inhibitors 
at hSERT (10-12). However, accessibility of a 
distinct binding pocket in the vestibule is 
likely to vary during transport activity and 
could therefore be sensitive to increasing 5HT 
concentrations. Furthermore, recent structural 
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simulations of LeuT have shown that the 
vestibule in LeuT holds a second substrate 
binding site (27). Thus, the vestibule in SERT 
might also have a second 5HT-binding site 
that is occupied during substrate permeation 
towards the central binding pocket. 
However, comprehensive mutational 
studies have identified residues in the 5HT-
binding pocket that are critical determinants 
for recognition of inhibitors (Fig. 1). In 
particular, Henry et al. (28) found that 
mutation of Ile172 on TM3 decreased potency 
of the SSRIs citalopram and fluoxetine by up 
to 2 orders of magnitude. Ile172 likely 
corresponds to Val104 in LeuT, which is 
located in the leucine binding pocket (2). 
Celik et al. (8) have recently verified that 
Ile172 has an ortholog position in the 
substrate binding site in SERT. TM3 is the 
antiparallel homolog of TM8 and it is 
noteworthy that Ser438 and Ile172 are located 
on opposite sides of the 5HT-binding pocket. 
Together these data are best explained by an 
overlapping binding site for 5HT and 
inhibitors in which Ile172 and Ser438 form 
direct contact points for inhibitor binding. 
However, differentiation between direct and 
indirect effects in mutagenesis studies is 
inherently difficult. Effects from a mutation 
could arise from a long-range allosteric effect 
that perturbs an inhibitor-binding site 
physically distinct from the 5HT pocket. A 
mutation could also induce a shift in 
equilibrium between the conformational states 
SERT assumes during substrate translocation. 
In both cases, the temporal accessibility of the 
inhibitor-binding site decreases. Indeed, it has 
been observed for imipramine that the 
dissociation rate is decreased in the presence 
of 5HT, which suggest cooperativity between 
two physically distinct binding sites (29). 
Therefore, the effects of mutation of Ile172 
and Ser438 cannot be interpreted 
unambiguously without substantiating direct 
interactions between these residues and the 
inhibitor molecule. In the present study, we 
address this problem by showing that analogs 
of TCAs and SSRIs with reciprocal chemical 
modifications become insensitive to the 
S438T mutation; substantiating a steric clash 
between the inhibitor aminopropyl moiety and 
the introduced protein methyl group as reason 
for the observed loss of potency. Similar 
approaches have previously been used to map 
specific interactions between 5HT-binding 
pocket residues and functional 5HT groups 
(8,22,23). This implies that the Ser438 side 
chain is within 3 Å of the ligand and likely 
constitutes a direct contact point for the 
aminopropyl group of these inhibitors. In 
comparison, the distance between the 
equivalent residue in LeuT, Ser355, and the 
TCA molecule within the structure of LeuT in 
complex with TCA is 18 Å (PDB code 
2QJU); thus suggesting the antidepressant-
binding pocket in LeuT and hSERT to be 
separate structural entities and supporting that 
5HT- and antidepressant-binding pockets 
overlaps in hSERT. 
While the I172M and S438T mutants 
specifically indicate that the location of the 
hSERT high-affinity binding pocket for 
citalopram and several TCAs is different from 
the LeuT TCA-binding pocket, the 
orthologous region in hSERT could still hold 
a secondary inhibitor-binding site. There is 
substantial evidence for the existence of a 
secondary low-affinity allosteric site that can 
modulate dissociation rates of several hSERT 
ligands from the high-affinity binding site 
(29). Although further experiments are 
needed to fully address the existence of 
functional relevant vestibule inhibitor-binding 
pocket, our observation that non-conservative 
mutations in this region in hSERT fail to alter 
inhibitor Ki indicate that, if present, such a 
binding site has little influence on the overall 
inhibitory mechanism. 
The results presented imply Ser438 as a 
direct contact for antidepressants bearing an 
aminopropyl group and provide further 
evidence for the location of a high-affinity 
antidepressant pocket in hSERT. Along with 
other SERT mutants, S438T is potentially 
useful for future studies of the structure of 
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this binding pocket and the mechanism of inhibition of antidepressants. 
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FIGURE LEGENDS 
 
Fig. 1. Topology of the human serotonin transporter. The substrate-binding pocket is formed 
by residues positioned in TM1, TM3, TM6 and TM8 (shown in grey). Residues elucidated as 
critical in recognition of SSRIs and TCAs are indicated: Tyr95 (30), Asp98 (23), Ala169 (31), 
Ile172 (28), Met180 (32), Ser276 (33), Phe513 (32), Ser545 (34) and Phe586 (35).  
 
Fig. 2. Mutation of Ser438 in the hSERT substrate binding pocket affects the inhibitory 
potency of antidepressants. A. Structure of LeuT in complex with leucine and desipramine (PDB 
code 2QJU). TM1 (blue), TM8 (green), and TM10 (pink) are highlighted. TM6 and TM11 are 
removed for clarity. Leucine and desipramine are shown as CPK representations in yellow and 
orange, respectively. Arg30 and Asp404 (shown as sticks) form the extracellular gate that separates 
leucine from the bound desipramine.  B. Left: Substrate binding site in LeuT (PDB code 2A65). 
Right: Homology model of the substrate binding site in hSERT. Conserved residues are shown in 
grey and divergent residues are shown in dark-red. TM1 (blue), TM6 (grey) and TM8 (green) are 
shown in both panels. C. Graphical summary of the fold change (mean ± S.E.M.; N=6-8) in potency 
of inhibitors at hSERT S438T compared to hSERT WT. Ki values and statistics are shown in Table 
1 and supplementary Table S1. # indicates that fold change is less than 1. D. Inhibition of 5HT 
uptake at hSERT WT (■) and S438T (□) by citalopram and aminoethyl citalopram. The shown 
concentration-response curve is a composite of six independent experiments. Error bars are S.E.M. 
and are shown when larger than symbol size. 
 
Fig. 3. Proposed working model for the impact of S438T mutation. Cartoon showing hSERT 
interaction with the aminopropyl chain of TCAs and SSRIs. Asp98 on TM1 (blue) coordinates the 
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aminopropyl group. Introduction of a methyl group at Ser438 on TM8 (green) by the S438T 
mutation leads to steric clash (indicated by the red stipulated line) with a methyl group on the 
aminopropyl chain. The steric clash is removed with monomethyl analogs.  
 
Fig. 4. Functional [3H]5HT uptake inhibition uptake analysis at hSERT WT and hSERT 
S438T. A. Upper: Structure of inhibitors having one (R = H) or two (R = CH3) methyl groups at the 
aminopropyl chain. Middle: Characterization of pairs of inhibitors having a single (■[WT]; 
▲[S438T]) or two (■[WT]; ▲[S438T]) methyl groups at the aminopropyl chain. Lower: Panel 
summarizes observed fold-change in Ki between WT and S438T for each inhibitor pair (mean ± 
S.E.M.; N=6-8). Ki values and statistics are shown in Table 1. 
 
 Fig. 5. Induced fit docking of (S)-citalopram (A) and imipramine (B). The highest scoring 
binding modes of both compounds are shown. TM1 (blue), TM3 and TM8 (green) are shown in 
both panels. Distances between the amine groups of the inhibitors and the carboxylate oxygen atom 
of Asp98 and the Cβ-atom of Ser438 are shown.         
 
Fig. 6. Impact of vestibule mutations in hSERT on inhibitor potency. A. Left: Structure of the 
TCA binding site in LeuT with imipramine bound (PDB code 2Q72). Right: Overlay of homology 
model of hSERT with LeuT structure (shown in left panel) to show the equivalent site in hSERT. 
TM1 (blue), TM3, TM6, EL4 and TM10 (pink) are shown. B. Graphical summary of fold change 
(mean ± S.E.M.; N=6-10) in potency of (S)-citalopram, imipramine and clomipramine at hSERT-
mutants compared to hSERT-WT. For comparison, the fold change in potency for (S)-citalopram, 
imipramine and clomipramine at S438T compared to hSERT WT are shown. Ki values and statistics 
are shown in supplementary Table S2. * indicates a significant change (P < 0.05) in Ki values. 
Table 1. Impact of hSERT S438T on [3H]5HT uptake inhibition constants for SERT inhibitors
The Ki-values for SERT inhibitors were determined at hSERT WT and hSERT S438T in a [3H]5HT uptake inhibition assay as described in ”Experimental
Procedures”. Data represents mean ± S.E.M. from at least 6 independent experiments (number of replicates given in parantheses) each performed in triplicate.
Th b f th l th i l h i f th i hibit i i di t d ** P < 0 01 *** P < 0 001 (St d t’ t t t)
R1 R2
Imipramine CH CH 153 9 ± 21 7 (6) 1070 6 ± 102 3 (6) 7 1 ± 0 3
Compound hSERT WT K i (nM) hSERT S438T K i (nM)
Affinity change
K i(S438T)/K i(WT)
e num er o me y -groups on e am nopropy c a n o e n ors s n ca e . , . ; , . u en s es .
3 3 . . . . . .
Desipramine CH3 H 1515.3 ± 173.7 (6) 2639.3 ± 351.2 (6) 1.7 ± 0.1
Clomipramine CH3 CH3 101.5 ± 32.7 (8) 717.9 ± 92.7 (8) 11.4 ± 2.4
Monomethyl-clomipramine CH3 H 589.5 ± 91.7 (8) 2294.9 ± 267.1 (8) 4.0 ± 0.2
A i i li CH CH 634 7 149 0 (8) 6044 8 733 9 (8) 11 5 1 4
***
**
m tr pty ne 3 3 . ± . . ± . . ± .
Nortriptyline CH3 H 3158.0 ± 587.8 (8) 2693.3 ± 334.4 (8) 0.9 ± 0.1
Citalopram CH3 CH3 59.3 ± 6.7 (6) 10038.3 ± 530.6 (6) 175.4 ± 11.9
Monomethyl-citalopram CH3 H 52.2 ± 4.6 (6) 303.1 ± 36.2 (6) 5.8 ± 0.5
***
***
***Des-methyl-citalopram H H 245.4 ± 42.0 (6) 392.3 ± 37.1 (6) 1.7 ± 0.2
(S )-Citalopram CH3 CH3 29.8 ± 5.2 (8) 7924.8 ± 659.8 (8) 320.1 ± 52.2
(S )-monomethyl-citalopram CH3 H 70.3 ± 13.6 (6) 774.1 ± 93.4 (6) 11.8 ± 0.9
***
Table 2. Impact of hSERT S438T on inhibition constants for competition of [3H]MADAM binding for SERT inhibitors
The Ki-values for SERT inhibitors were determined at hSERT WT and hSERT S438T in a [3H]MADAM competition binding assay as described in
”Experimental Procedures”. Data represents mean ± S.E.M. from at least 3 independent experiments (number of replicates given in parantheses) each
f d i d bli t Th b f th l th i l h i f th i hibit i i di t d ** P < 0 01 (St d t’ t t t)per orme n u ca e. e num er o me y -groups on e am nopropy c a n o e n ors s n ca e . , . u en s es .
R1 R2
I i i CH CH 8 9 ± 1 1 (6) 1875 5 ± 572 4 (4) 282 6 ± 142 7
Affinity change
K i(S438T)/K i(WT)
hSERT WT K i (nM) hSERT S438T K i (nM)Compound
m pram ne 3 3 . . . . . .
Desipramine CH3 H 237.7 ± 55.6 (5) 2038.0 ± 292.8 (4) 11.0 ± 3.9
Clomipramine CH3 CH3 0.6 ± 0.2 (7) 110.9 ± 52.5 (4) 107.2 ± 36.3
Monomethyl-clomipramine CH3 H 11.2 ± 2.7 (7) 114.3 ± 66.3 (3) 8.9 ± 1.1
A i i li CH CH 24 8 1 ( ) 498 2 113 2 (3) 19 6
**
**
m tr pty ne 3 3 . ± 7. 7 . ± . .7 ± .5
Nortriptyline CH3 H 156.5 ± 37.8 (5) 289.9 ± 169.0 (4) 2.6 ± 1.7
Citalopram CH3 CH3 7.4 ± 1.9 (8) 9699.0 ± 1288.6 (4) 2148.3 ± 1004.0
Monomethyl-citalopram CH3 H 19.8 ± 2.5 (5) 155.7 ± 34.0 (4) 7.9 ± 1.0
**
**
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